Future research should further explore the potential of CXCR4-targeted PET imaging in selecting patients with triple-negative breast cancer and high-grade breast cancer who may benefit from CXCR4-targeted therapies and monitoring response to therapy, particularly in the context of HIV co-infection. This evidence concerns the gene CXCR4 and triple-negative breast carcinoma.